Jean-Pierre Tirouflet
Plus aucun poste en cours
Profil
Jean-Pierre Tirouflet served as Chairman & CEO of Rhodia Chimie SAS and CEO of BioSystems International SAS from 2009 to 2014.
He was also Chairman of MEDEF Paris in 2004.
Prior to that, he was a Director at Altadis SA from 2001 to 2008.
He served as Principal at the European Union from 1978 to 1980 and was President of the European Chemical Group Eurochimic in 2002.
Tirouflet received his undergraduate degree from Ecole Nationale d'Administration in 1976.
Anciens postes connus de Jean-Pierre Tirouflet
| Sociétés | Poste | Fin |
|---|---|---|
BioSystems International SAS
 BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Directeur Général | 06/03/2014 |
Altadis SA
 Altadis SA TobaccoConsumer Non-Durables Altadis SA engages in the manufacture and distribution of tobacco products. These include cigars and cigarettes. It also offers pipe tobacco and chewing tobacco, and accessories such as rolling paper, cutters, lighters, and storage boxes. The company was founded in 1887 and is headquartered in Madrid, Spain. | Directeur/Membre du Conseil | 25/02/2008 |
| MEDEF Paris | Président | 01/01/2004 |
European Chemical Group Eurochimic
 European Chemical Group Eurochimic Household/Personal CareConsumer Non-Durables Part of Ecolab, Inc., European Chemical Group Eurochimic is a French company that manufactures cleaning products. The company is located in France. European Chemical Group Eurochimic was acquired by Laboratoires Anios SAS, part of Ecolab, Inc. from February 01, 2017 on November 01, 1998. | President | 01/01/2002 |
European Union
 European Union SupranationalGovernment Supranational | Corporate Officer/Principal | 01/01/1980 |
Formation de Jean-Pierre Tirouflet
| Ecole Nationale d'Administration | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Altadis SA
Altadis SA TobaccoConsumer Non-Durables Altadis SA engages in the manufacture and distribution of tobacco products. These include cigars and cigarettes. It also offers pipe tobacco and chewing tobacco, and accessories such as rolling paper, cutters, lighters, and storage boxes. The company was founded in 1887 and is headquartered in Madrid, Spain. | Consumer Non-Durables |
Rhodia Chimie SAS
 Rhodia Chimie SAS Chemicals: SpecialtyProcess Industries Rhodia Chimie SAS produces specialty chemicals for food products. The company has partnerships with the automotive, electronic, health and other related sectors. The firm is headquartered in Boulogne-Billancourt, France. | Process Industries |
European Union
European Union SupranationalGovernment Supranational | Government |
European Chemical Group Eurochimic
European Chemical Group Eurochimic Household/Personal CareConsumer Non-Durables Part of Ecolab, Inc., European Chemical Group Eurochimic is a French company that manufactures cleaning products. The company is located in France. European Chemical Group Eurochimic was acquired by Laboratoires Anios SAS, part of Ecolab, Inc. from February 01, 2017 on November 01, 1998. | Consumer Non-Durables |
BioSystems International SAS
BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
| MEDEF Paris |
